Safety and Effectiveness of Left Atrial Appendage Closure in Atrial Fibrillation (SAFELY-AF)

左心耳封堵术治疗心房颤动 (SAFELY-AF) 的安全性和有效性

基本信息

  • 批准号:
    10221038
  • 负责人:
  • 金额:
    $ 71.81万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2019
  • 资助国家:
    美国
  • 起止时间:
    2019-09-01 至 2023-06-30
  • 项目状态:
    已结题

项目摘要

PROJECT SUMMARY. Atrial fibrillation (AF) is the most common cardiac arrhythmia and markedly increases the risk for stroke and systemic embolism. Oral anticoagulation has been the mainstay of therapies to reduce the risk of stroke and systemic embolism in AF, but studies have consistently shown that between 30-50% of patients for whom oral anticoagulation is indicated are not treated with anticoagulants. Left atrial appendage occlusion (LAAO) represents a new and increasingly important device-based approach for preventing stroke and thromboembolism in AF patients. Randomized trials have evaluated LAAO for the prevention of stroke and thromboembolism in atrial fibrillation, but the trial results were inconsistent, leaving important gaps in knowledge regarding the safety and effectiveness of this procedure. The goal of this proposal, “Safety and Effectiveness of Left Atrial Appendage Occlusion in Atrial Fibrillation (SAFELY-AF)”, is to leverage data from a large national registry of LAAO procedures to enhance our understanding of the use and effectiveness of LAAO in real-world practice. The National Cardiovascular Data Registry’s LAAO Registry represents the largest prospective registry of LAAO procedures worldwide. Through a novel collaboration with Boston Scientific and the American College of Cardiology (ACC), we propose a series of studies that will enhance our understanding of the use and effectiveness of LAAO in real-world practice. First, we will use patient-level data from the pivotal randomized trials of LAAO devices and data from the NCDR LAAO Registry to examine differences in patient characteristics and outcomes following device implantation. We will further identify patient, physician, and hospital predictors of adverse outcomes following device implantation and use this information to develop a risk score to determine major adverse events. This information will be incorporated into the ACC’s shared decision making (SDM) tool, developed to promote shared decision-making for patients and physicians regarding LAAO procedures. Finally, we will conduct comparative-effectiveness research, using cutting-edge computational approaches to characterize the association between different approaches to periprocedural antithrombotic and anticoagulant therapies and patient outcomes following device implantation.
项目摘要。心房颤动(AF)是最常见的心律失常, 中风和全身性栓塞的风险。口服抗凝剂一直是治疗的支柱,以减少 房颤患者中风和全身性栓塞的风险,但研究一致表明, 需要口服抗凝剂的患者不用抗凝剂治疗。左心耳 闭塞(LAAO)代表了一种新的且日益重要的预防卒中的基于器械的方法 和血栓栓塞。随机试验评价了LAAO预防卒中的作用, 房颤血栓栓塞,但试验结果不一致,留下了重要的差距, 了解本程序的安全性和有效性。该提案的目标是“安全和 房颤患者左心房封堵术的有效性(SAFELY-AF)",旨在利用来自 LAAO程序的大型国家登记册,以提高我们对LAAO程序的使用和有效性的理解。 在现实世界中的实践。国家心血管数据登记中心的LAAO登记中心代表了 全球最大的LAAO手术前瞻性登记研究。通过与波士顿的新颖合作, 科学和美国心脏病学会(ACC),我们提出了一系列的研究,将提高我们的 了解LAAO在现实世界实践中的使用和有效性。首先,我们将使用患者水平的数据 来自LAAO器械的关键随机试验和来自NCDR LAAO登记研究的数据, 器械植入后患者特征和结局的差异。我们将进一步确定 器械植入后不良结局的患者、医生和医院预测因素,并使用此 信息,以制定风险评分,以确定主要不良事件。这些信息将被纳入 ACC的共享决策(SDM)工具,旨在促进患者的共享决策 和医生进行LAAO手术。最后,我们将使用 尖端的计算方法来表征不同方法之间的关联, 围手术期抗血栓和抗凝治疗以及器械植入后的患者结局。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

James Freeman其他文献

James Freeman的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('James Freeman', 18)}}的其他基金

Safety and Effectiveness of Left Atrial Appendage Closure in Atrial Fibrillation (SAFELY-AF)
左心耳封堵术治疗心房颤动 (SAFELY-AF) 的安全性和有效性
  • 批准号:
    10431910
  • 财政年份:
    2019
  • 资助金额:
    $ 71.81万
  • 项目类别:
Comparative effectiveness of catheter ablation vs medical therapy for atrial fibr
导管消融与药物治疗对心房纤维的疗效比较
  • 批准号:
    8725227
  • 财政年份:
    2013
  • 资助金额:
    $ 71.81万
  • 项目类别:
Comparative effectiveness of catheter ablation vs medical therapy for atrial fibr
导管消融与药物治疗对心房纤维的疗效比较
  • 批准号:
    8852701
  • 财政年份:
    2013
  • 资助金额:
    $ 71.81万
  • 项目类别:
Comparative effectiveness of catheter ablation vs medical therapy for atrial fibr
导管消融与药物治疗对心房纤维的疗效比较
  • 批准号:
    8487609
  • 财政年份:
    2013
  • 资助金额:
    $ 71.81万
  • 项目类别:
Comparative effectiveness of catheter ablation vs medical therapy for atrial fibr
导管消融与药物治疗对心房纤维的疗效比较
  • 批准号:
    9065739
  • 财政年份:
    2013
  • 资助金额:
    $ 71.81万
  • 项目类别:

相似海外基金

Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
  • 批准号:
    10707830
  • 财政年份:
    2023
  • 资助金额:
    $ 71.81万
  • 项目类别:
Hospital characteristics and Adverse event Rate Measurements (HARM) Evaluated over 21 years.
医院特征和不良事件发生率测量 (HARM) 经过 21 年的评估。
  • 批准号:
    479728
  • 财政年份:
    2023
  • 资助金额:
    $ 71.81万
  • 项目类别:
    Operating Grants
Analysis of ECOG-ACRIN adverse event data to optimize strategies for the longitudinal assessment of tolerability in the context of evolving cancer treatment paradigms (EVOLV)
分析 ECOG-ACRIN 不良事件数据,以优化在不断发展的癌症治疗范式 (EVOLV) 背景下纵向耐受性评估的策略
  • 批准号:
    10884567
  • 财政年份:
    2023
  • 资助金额:
    $ 71.81万
  • 项目类别:
AE2Vec: Medical concept embedding and time-series analysis for automated adverse event detection
AE2Vec:用于自动不良事件检测的医学概念嵌入和时间序列分析
  • 批准号:
    10751964
  • 财政年份:
    2023
  • 资助金额:
    $ 71.81万
  • 项目类别:
Understanding the real-world adverse event risks of novel biosimilar drugs
了解新型生物仿制药的现实不良事件风险
  • 批准号:
    486321
  • 财政年份:
    2022
  • 资助金额:
    $ 71.81万
  • 项目类别:
    Studentship Programs
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
  • 批准号:
    10676786
  • 财政年份:
    2022
  • 资助金额:
    $ 71.81万
  • 项目类别:
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
  • 批准号:
    10440970
  • 财政年份:
    2022
  • 资助金额:
    $ 71.81万
  • 项目类别:
Improving Adverse Event Reporting on Cooperative Oncology Group Trials
改进肿瘤学合作组试验的不良事件报告
  • 批准号:
    10642998
  • 财政年份:
    2022
  • 资助金额:
    $ 71.81万
  • 项目类别:
Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
  • 批准号:
    10482465
  • 财政年份:
    2022
  • 资助金额:
    $ 71.81万
  • 项目类别:
Expanding and Scaling Two-way Texting to Reduce Unnecessary Follow-Up and Improve Adverse Event Identification Among Voluntary Medical Male Circumcision Clients in the Republic of South Africa
扩大和扩大双向短信,以减少南非共和国自愿医疗男性包皮环切术客户中不必要的后续行动并改善不良事件识别
  • 批准号:
    10191053
  • 财政年份:
    2020
  • 资助金额:
    $ 71.81万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了